AzarGen Biotechnologies Overview
- Founded
-
2003
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$3.1M
- Investors
-
2
AzarGen Biotechnologies General Information
Description
Developer of human therapeutic proteins designed to increase the survivability of premature-born infants. The company's human therapeutic proteins are made using advanced plant-based genetic engineering and synthetic biology techniques and it also offers a plant-based expression technology that comprises optimal combinations of novel synthetic promoters, combined with enhancer and purification components, enabling medical professionals to offer drugs with superior clinical efficacy at low cost that can significantly improve the health status of citizens.
Contact Information
Website
www.azargen.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Primary Office
- Launchlab Hammandshand Road
- Stellenbosch
- Cape Town, 7600
- South Africa
+27 021 000 0000
AzarGen Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC (Series B) | 07-Jan-2016 | $3.1M | 00.00 | Completed | Generating Revenue | |
| 1. Grant | Completed | Startup |
AzarGen Biotechnologies Patents
AzarGen Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2015262984-A1 | Synthetic promoter construct for transgene expression | Abandoned | 19-May-2014 | 00000000000 | |
| CA-2947805-A1 | Synthetic promoters for transgene expression in plants | Abandoned | 19-May-2014 | 00000000000 | |
| EP-3146053-A1 | Synthetic promoter construct for transgene expression | Withdrawn | 19-May-2014 | 00000000000 | |
| US-9670497-B2 | Synthetic promoter construct for transgene expression | Active | 19-May-2014 | 00000000000 | 0 |
| US-20150329869-A1 | Synthetic promoter construct for transgene expression | Granted | 19-May-2014 | C12N15/8216 | 0 |
AzarGen Biotechnologies Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Mauritz Venter Ph.D | Co-Founder & Chief Executive Officer | ||
| Cobus Zwiegelaar Ph.D | Co-Founder, Chief Operating Officer & Director |
AzarGen Biotechnologies Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
AzarGen Biotechnologies Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Industrial Development Corporation of South Africa | Corporation | Minority | 000 0000 | 000000 0 | |
| South African Government | Government | 000 0000 | 000000 0 |